- CSL Limited (ASX:CSL) Publishes its Fifth Corporate Responsibility Report - CSL Limited (ASX:CSL) Publishes its Fifth Corporate Responsibility Report

The report details the company's performance across six key corporate responsibility priority areas
Tuesday, December 3, 2013 - 5:00am

CAMPAIGN: ReportAlerts from 2013

CONTENT: Press Release

December 3, 2013 /3BL Media/ - CSL Limited has published its fifth Corporate Responsibility Report - Our Corporate Responsibility 2013 - available at:

The report details CSL’s performance across six key corporate responsibility priority areas for the period 1 July 2012 and 30 June 2013.

Highlights and statistics include:

  • Economic contribution direct to local economies of US$4.7 billion, including global community investment of US$36 million to patient, biomedical and local communities;
  • Release of an updated edition of CSL’s Code of Responsible Business Practice in 15 languages. Its workforce participated in another global employee opinion survey, with achievement of organisational goals and quality & compliance ranked as the most outstanding company characteristic;
  • Research and Development investment of US$427 million, with more than 35 clinical studies in operation across its pipeline. CSL also achieved 17 product registrations/ indications for serious diseases;
  • More than 180 regulatory audits of CSL’s manufacturing facilities with no impact on its product marketing licences. Efforts to harmonise safety and quality processes across the organisation continue;
  • Growth of 7% in the total workforce. Incidents involving medical treatment rose by 41%, but recorded rates of lost time injury frequency and days lost frequency reduced by 8% and 74% respectively;
  • Minor increases in absolute measures across CSL’s environmental impacts, in part due to capacity expansion initiatives, however CSL achieved modest reductions in the amount of energy, greenhouse gas and water used to process each unit of plasma.

The CSL Group has a combined heritage of outstanding contribution to medicine and human health with just under 100 years’ experience in the development and manufacture of vaccines and plasma protein biotherapies. With major facilities in Australia, Germany, Switzerland and the USA, CSL has over 12,000 employees working in more than 25 countries.

Please provide feedback on CSL’s Report at: